129101-54-8 Rivastigmine tartrate AKSci J10584
 
 
Loading Please Wait...
  J10584    
Rivastigmine tartrate
, >98% (HPLC)
 
N-Ethyl-N-methylcarbamic Acid 3-[(S)-1-(Dimethylamino)ethyl]phenyl Ester L-Tartrate




IDENTITY
CAS Number:129101-54-8
MDL Number:MFCD03700731
MF:C14H22N2O2.C4H6O6
MW:400.42
SPECIFICATIONS & PROPERTIES
Purity:>98% (HPLC)
Spectra:NMR, LCMS, HPLC
Physical Form:White to off-white crystalline powder
Melting Point:115-128°C
Optical Rotation:+4.7° (c=5, EtOH)
Long-Term Storage:Store at room temperature
UN #:UN2811
Hazard Class:6.1
Packing Group:III

BIOLOGICAL INFO
Solubility:EtOH; MeOH
Application(s):Cholinesterase inhibitor

REVIEW

 Rivastigmine is a carbamate derivative that is structurally related to physostigmine, but not to donepezil and tacrine. The precise mechanism of rivastigmine has not been fully determined, but it is suggested that rivastigmine binds reversibly with and inactivates chlolinesterase (eg. acetylcholinesterase, butyrylcholinesterase), preventing the hydrolysis of acetycholine, and thus leading to an increased concentration of acetylcholine at cholinergic synapses. The anticholinesterase activity of rivastigmine is relatively specific for brain acetylcholinesterase and butyrylcholinesterase compared with those in peripheral tissues.

REFERENCES
[1]Camps P, Munoz-Torrero D: Cholinergic drugs in pharmacotherapy of Alzheimer's disease. Mini Rev Med Chem. 2002 Feb;2(1):11-25.
[2] Rosler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stahelin HB, Hartman R, Gharabawi M: Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ. 1999 Mar 6;318(7184):633-8.
[3] Finkel SI: Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer's disease. Clin Ther. 2004 Jul;26(7):980-90.
[4] Rosler M, Retz W, Retz-Junginger P, Dennler HJ: Effects of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease. Behav Neurol. 1998;11(4):211-216.

GHS

Pictograms

Signal Word
Warning

Hazard Statements
H315; H319; H335

Precautionary Statements
P261; P264; P271; P280; P302+P352; P304+P340; P305+P351+P338; P312; P321; P332+P313; P337+P313; P362; P403+P233; P405; P501


Current as of January 18, 2019


Download SDS

CATEGORIES

 APIs and Bioactives > AChR Agonists, Alzheimer's


PubChem